# A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

> **NCT05291234** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 106 (actual)

## Conditions studied

- Alzheimer's Disease (AD)

## Interventions

- **DRUG:** ABBV-916
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05291234
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-15
- **Primary completion:** 2025-11-19
- **Final completion:** 2025-11-19
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05291234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05291234, "A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05291234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*